CD33修饰的造血干细胞后代在恒河猴中免受CD33导向CAR T细胞攻击
研究在恒河猴中移植经CRISPR/Cas9或腺嘌呤碱基编辑器编辑以消除CD33的造血干细胞和祖细胞(HSPCs),两种编辑策略移植后恢复动力学相似且植入水平相当。随后用自体CD33特异性CAR T细胞(CAR33)治疗,CAR33 T细胞输注后扩增并特异性清除CD33野生型而非CD33缺失的后代,导致血液中基因编辑细胞短暂富集,骨髓干细胞隔室未见清除。
要点
- 在恒河猴中验证了基于表位编辑的富集/保护策略的概念与安全性。
- CAR33 T细胞输注后扩增并特异性清除CD33野生型细胞,使血液中基因编辑细胞短暂富集。
- 骨髓中CD34+CD90+造血干细胞CD33表达低于单核细胞,未发生清除。
核心结论
- 在恒河猴中证明了基于表位编辑的富集/保护策略的概念与安全性。
研究设计与样本
- 恒河猴移植经CRISPR/CRISPR相关蛋白9或腺嘌呤碱基编辑器编辑消除CD33的造血干细胞和祖细胞(HSPCs),随后用自体CAR33 T细胞治疗。
主要发现
- 两种编辑策略移植后恢复动力学相似,植入水平相当。
- CAR33 T细胞输注后扩增,特异性清除CD33野生型而非CD33缺失的后代,导致血液中基因编辑细胞短暂富集。
- 骨髓干细胞隔室未见清除,CD34+CD90+造血干细胞CD33表达低于单核细胞。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The treatment of monogenetic disorders, such as hemoglobinopathies and lysosomal storage diseases, has markedly improved with the advent of cell and gene therapies, particularly allogeneic or gene-modified autologous stem cell transplantations. However, therapeutic efficacy is reliant on maintaining engraftment above a critical threshold. To maintain such engraftment levels, we and others have pursued approaches to shield edited cells from antibody or chimeric antigen receptor (CAR) T-cell-mediated selection. Here, we focused on CD33, which is expressed early on hematopoietic stem and progenitor cells (HSPCs) as well as on myeloid progenitors. Rhesus macaques were engrafted with HSPCs edited to ablate CD33 using either CRISPR/CRISPR-associated protein 9 or adenine base editor. Both editing strategies showed similar post-transplant recovery kinetics and yielded equivalent levels of engraftment. We then created a V-set domain-specific CAR construct (CAR33), validated its functionality in vitro, and treated both animals with autologous CAR33 T cells. CAR33 T cells expanded after infusion and caused specific depletion of CD33WT but not CD33null progeny, leading to a transient enrichment for gene-edited cells in the blood. No depletion was seen in the bone marrow stem cell compartment with CD34+CD90+ HSCs expressing lower levels of CD33 in comparison to monocytes. Thus, we show proof of concept and safety of an epitope editing-based enrichment/protection strategy in macaques.
引用
- Petty NE, Radtke S, Kanestrom G, et al. Protection of CD33-modified hematopoietic stem cell progeny from CD33-directed CAR T cells in rhesus macaques. Blood Adv. 2025. PMID: 39928955. doi:10.1182/bloodadvances.2024015016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。